Benjamin F. Edwards & Company Inc. cut its stake in Sanofi (NYSE:SNY) by 26.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,213 shares of the company’s stock after selling 5,610 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Sanofi were worth $729,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SNY. Fisher Asset Management LLC increased its position in Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock valued at $653,419,000 after buying an additional 1,022,953 shares during the period. Bank of America Corp DE increased its position in Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock valued at $340,792,000 after buying an additional 572,652 shares during the period. Wells Fargo & Company MN increased its position in Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares during the period. Brandes Investment Partners LP increased its position in Sanofi by 3.0% in the first quarter. Brandes Investment Partners LP now owns 3,490,226 shares of the company’s stock valued at $157,933,000 after buying an additional 102,511 shares during the period. Finally, Hamlin Capital Management LLC increased its position in Sanofi by 11.8% in the first quarter. Hamlin Capital Management LLC now owns 1,768,523 shares of the company’s stock valued at $80,026,000 after buying an additional 186,280 shares during the period. 9.90% of the stock is owned by institutional investors.
Shares of Sanofi (SNY) opened at 48.19 on Friday. The firm has a 50-day moving average of $47.84 and a 200-day moving average of $46.41. The company has a market cap of $121.03 billion, a price-to-earnings ratio of 11.43 and a beta of 0.88. Sanofi has a one year low of $36.81 and a one year high of $50.24.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.74. The firm had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The firm’s revenue was down 2.3% on a year-over-year basis. Equities research analysts forecast that Sanofi will post $3.26 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Benjamin F. Edwards & Company Inc. Has $729,000 Position in Sanofi (SNY)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.com-unik.info/2017/08/19/sanofi-sny-stake-decreased-by-benjamin-f-edwards-company-inc-updated-updated.html.
Several analysts have issued reports on the stock. Argus increased their target price on shares of Sanofi from $50.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, June 9th. Cowen and Company reiterated a “market perform” rating and issued a $52.00 target price (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Monday, April 24th. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $54.00.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.